NCT06870994View on ClinicalTrials.gov

Intratumoral Targeted Hyperthermia Therapy (THT) for Cutaneous Metastatic Melanoma

NANot yet recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

July 1, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Cutaneous Metastatic Melanoma
Interventions
DEVICE

Targeted Hyperthermia Therapy

Intra-tumoral gold nanorods (SivaRods) exposed to Near Infrared Light (860 +/- 10nm) mediated targeted hyperthermia therapy

All Listed Sponsors
collaborator

Nova Scotia Health Authority

OTHER

lead

Sona Nanotech Inc

INDUSTRY

NCT06870994 - Intratumoral Targeted Hyperthermia Therapy (THT) for Cutaneous Metastatic Melanoma | Biotech Hunter | Biotech Hunter